The interplay of UBE2T and Mule in regulating Wnt/β-catenin activation to promote hepatocellular carcinoma progression
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The interplay of UBE2T and Mule in regulating Wnt/β-catenin activation to promote hepatocellular carcinoma progression
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 12, Issue 2, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-04
DOI
10.1038/s41419-021-03403-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- UBE2T promotes proliferation via G2/M checkpoint in hepatocellular carcinoma
- (2019) Li-Li Liu et al. Cancer Management and Research
- Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway
- (2018) Regina Cheuk-Lam Lo et al. CELL DEATH AND DIFFERENTIATION
- Ubiquitin-conjugating enzyme UBE2O regulates cellular clock function by promoting the degradation of the transcription factor BMAL1
- (2018) Suping Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Characterization of the GNMT-HectH9-PREX2 tripartite relationship in the pathogenesis of hepatocellular carcinoma
- (2017) Chung-Hsien Li et al. INTERNATIONAL JOURNAL OF CANCER
- E3 ubiquitin ligase Mule targets β-catenin under conditions of hyperactive Wnt signaling
- (2017) Carmen Dominguez-Brauer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- UBE2T knockdown inhibits gastric cancer progression
- (2017) Changjiang Luo et al. Oncotarget
- E2 enzymes: more than just middle men
- (2016) Mikaela D Stewart et al. CELL RESEARCH
- Mule Regulates the Intestinal Stem Cell Niche via the Wnt Pathway and Targets EphB3 for Proteasomal and Lysosomal Degradation
- (2016) Carmen Dominguez-Brauer et al. Cell Stem Cell
- Octamer 4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in liver cancer stem cells
- (2016) Stella Chai et al. HEPATOLOGY
- Knockdown of UBE2T Inhibits Osteosarcoma Cell Proliferation, Migration, and Invasion by Suppressing the PI3K/Akt Signaling Pathway
- (2016) Yu Wang et al. ONCOLOGY RESEARCH
- Ubiquitin-Conjugating Enzyme E2T is an Independent Prognostic Factor and Promotes Gastric Cancer Progression
- (2016) Hao Yu et al. TUMOR BIOLOGY
- CSCdb: a cancer stem cells portal for markers, related genes and functional information
- (2016) Yi Shen et al. Database-The Journal of Biological Databases and Curation
- Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer
- (2015) Mingxin Wen et al. Oncotarget
- Obesity Promotes Liver Carcinogenesis via Mcl-1 Stabilization Independent of IL-6Rα Signaling
- (2013) Sabine Gruber et al. Cell Reports
- CD24+ Liver Tumor-Initiating Cells Drive Self-Renewal and Tumor Initiation through STAT3-Mediated NANOG Regulation
- (2011) Terence Kin Wah Lee et al. Cell Stem Cell
- Stem Cells in Hepatocarcinogenesis: Evidence from Genomic Data
- (2010) Jens Marquardt et al. SEMINARS IN LIVER DISEASE
- Ubiquitination and Downregulation of BRCA1 by Ubiquitin-Conjugating Enzyme E2T Overexpression in Human Breast Cancer Cells
- (2009) T. Ueki et al. CANCER RESEARCH
- FANCI Binds Branched DNA and Is Monoubiquitinated by UBE2T-FANCL
- (2009) Simonne Longerich et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting the ubiquitin-proteasome system for cancer therapy
- (2008) Yili Yang et al. CANCER SCIENCE
- EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features
- (2008) Taro Yamashita et al. GASTROENTEROLOGY
- Elevated Expression of UBE2T in Lung Cancer Tumors and Cell Lines
- (2008) Jia Hao et al. TUMOR BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started